1Assistant Professor, Department of Pharmaceutics, Vivekanandha Pharmacy College for Women, Veerachipalayam, Sankagiri West, Sankagiri Taluk, Salem District-637303.
2Vivekanandha Pharmacy College for Women, Veerachipalayam, Sankagiri West, Sankagiri Taluk, Salem District-637303
Omaveloxolone is a semisynthetic triterpenoid used to treat friedreich’s ataxia. It is the second generation oleananetriterpenoid Nrf2 inducer with antioxidant and anti-inflammatory properties. It is currently used to test in medical trials for freidreich’s ataxia, a genetic, multi –organ disease involving mitochondrial dysfunction. It is a nuclear factor erythroid 2 related factor 2 (Nrf2) activator. It is reviewed under Food and Drug Administration and it has the potential to first approved treatment for friedreich’s ataxia. Omaveloxolone is not the cure for friedreich’s ataxia, it is the first agent targeting to reach NDA submission. It is the rational and potent therapy that is probably disease modifying in the treatment of friedreich’s ataxia. Omaveloxolone (RTA-408) is an Nrf2 activator, which decreases the susceptibility of cells through oxidative stress and it leads to cell death and tissue degradation. It is good tolerated not having any significant long term adverse effects. Treatment with RTA-408 remarkably improved in the neurological function, it is measured by modified Freidreich’s Ataxia Rating Scale.
Lalitha A., Nanjundeshwari G., Swetha M., Swetha R., A Review On Omaveloxolone, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 9, 447-456. https://doi.org/10.5281/zenodo.8383431